December 19, 2006 – GlaxoSmithKline paid a record breaking $2.1 billion to in-license a cancer/arthritis drug candidate from Genmab A/S; Wyeth received priority review for cancer drug Torisel; interim data from GenVec drug TNFerade showed a survival increase of 42.5%; Geron said its telomerase inhibitor may benefit breast cancer patients receiving radiation; Human Genome Sciences began a Phase III test of Albuferon in patients with hepatitis C; MedImmune in-licensed an asthma monoclonal antibody from BioWa; Gilead Sciences requested approval of ambrisentan for PAH; BioMarin reported positive data for Phenoptin; Prana began dosing patients in a Phase IIa trial of an Alzheimer’s drug; Crucell received permission to begin a Phase I trial of its malaria vaccine; and Lilly will enter a drug discovery collaboration with PsychoGenics. The Centient Biotech 200™ traded up 2 points to 3952, a rise of .05%. More details...
